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Abstract
Background: The aim of this study was to evaluate the value of device-based diagnostic parame-
ters in predicting ventricular arrhythmias in cardiac resynchronization therapy (CRT) recipients.
Methods: Ninety-six CRT-D patients participating in TRUST CRT Trial were analyzed. The 
inclusion criteria were: heart failure in NYHA ≥ 3 class, QRS ≥ 120 ms, LVEF £ 35% and 
significant mechanical dyssynchrony. Patients were divided into those with (n = 31, 92 arrhyth-
mias) and without (n = 65) appropriate ICD interventions within follow-up of 12.03 ± 6.7 
months. Daily monitored device-based parameters: heart rate (HR), thoracic impedance (TI),  
HR variability and physical activity were analyzed in 4 time windows: within 10, 7, 3 days 
and 1 day before appropriate ICD interventions.
Results: A consistent pattern of changes in three monitored factors was observed prior to ar-
rhythmia: 1) a gradual increase of day HR (from 103.43% of reference within 10-day window 
to 105.55% one day before, all p < 0.05 vs. reference); 2) variations in night HR (104.75% 
in 3 days, 107.65% one day before, all p < 0.05) and 3) TI decrease (from 97.8% in 10 days 
to 96.81% one day before, all p < 0.05). The combination of three parameters had better pre-
dictive value, which improved further after exclusion of patients with atrial fibrillation (AF). 
The predictive model combining HR and TI together with LVEF and NT-proBNP was more 
prognostic than the model involving LVEF and NT-proBNP alone (difference in AUC 0.05, 
95% CI 0.0005–0.09, p = 0.04).
Conclusions: Daily device-monitored parameters show significant variations prior to ven-
tricular arrhythmia. Combination of multiple parameters improves arrhythmia predictive 
performance by its additive value to baseline risk factors, while presence of AF diminishes it. 
(Cardiol J 2014; 21, 4: 405–412)
Key words: device-based monitoring, cardiac resynchronization therapy,  
ventricular arrhythmia, intrathoracic impedance, heart rate, heart failure
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Introduction
Despite the positive effects of biventricular 
pacing [1–5], heart failure (HF) patients still remain 
at increased risk of life-threatening ventricular 
arrhythmias. Appropriate shocks are associated 
with increased risk of death [6]. Presently im-
planted devices are capable of measuring various 
parameters such as averaged heart rates, heart 
rate variability (HRV), patient physical activity 
and intra-thoracic impedance (TI). Some studies 
indicated that changes in these measures are as-
sociated with increased hospitalization rates due 
to exacerbated HF [7, 8]. Little is known about 
the changes in device-measured parameters that 
occur prior to malignant arrhythmias, which would 
make it possible to predict serious arrhythmic 
events. The aim of this study was to evaluate the 
prognostic value of daily monitored device-based 
diagnostic parameters as predictors of malignant 
ventricular arrhythmias in patients undergoing 
cardiac resynchronization therapy (CRT).
Methods
Study population
Study population consisted of patients in-
cluded in the Triple-Site Versus Standard Cardiac 
Resynchronization Therapy Trial (TRUST CRT) 
which was a prospective, randomized, single cen-
ter trial to assess the effectiveness of triple-site 
pacing versus standard resynchronization therapy 
[9]. The study included HF patients in New York 
Heart Association (NYHA) class III–IV, with sinus 
rhythm, QRS width ≥ 120 ms, left ventricular 
ejection fraction (LVEF) £ 35% and significant 
(≥ 40 ms) inter- or intra-ventricular mechanical 
dyssynchrony.
Patients were randomized in a 1:1 ratio to 
conventional or triple-site (dual-left, single-right) 
CRT-D. The enrollment began in February 2008 
and was accomplished in January 2010, when 100 
consecutive patients were enrolled. All patients 
were implanted with CRT-D devices (InSync III 
Sentry, Medtronic, Minneapolis, USA) capable of 
continuous monitoring and storing daily variations 
of several parameters. Study protocol and procedur-
al outcomes had been published previously [9, 10]. 
Two patients, in whom the implantation of CRT-D 
failed were not analyzed in the study. Two other 
subjects were excluded after enrollment (lung 
cancer in one patient, non-compliance in the sec-
ond one). Data from 96 patients were used for the 
analysis.
The study was approved by the local bioethi-
cal committee and all patients gave their informed 
consent.
Device settings and reprogramming
The pacing and antiarrhythmic settings of 
CRT-D were programmed identically in all patients 
(DDD mode, lower pacing rate of 50 bpm, ven-
tricular tachycardia (VT) zone 150–200 bpm, ven-
tricular fibrillation (VF) zone > 200 bpm). Paced 
and sensed atrio-ventricular and inter-ventricu-
lar delays were optimized echocardiographically 
1–3 days after the implantation [9]. All patients 
were kept on pre-discharge settings of CRT-D dur-
ing the follow-up and no further routine reprogram-
ming was allowed unless clear indications occurred.
Follow-up, classification of antiarrhythmic 
interventions and adverse events
All patients were followed on outpatient basis 
for 1 week, 1, 3 and 6 months after randomiza-
tion and every 6 months thereafter. Antiarrhyth-
mic therapies were assessed independently by 
2 members of the Arrhythmic Events Assess-
ment Board.
Data on potential adverse events were collect-
ed throughout the entire follow-up and adjudicated 
blindly by 2 experts. Arrhythmia was considered 
temporarily related to HF exacerbation if its occur-
rence was followed by HF hospitalization within 
next 10 days, or if arrhythmia occurred during 
hospitalization due to HF exacerbation.
Device-based measurements and collection 
of data retrieved from pacemakers’ memory
At 3-month follow-up and every 6 months 
thereafter, biometric data collected continuously 
by devices were downloaded, converted into elec-
tronic format (Microsoft Excel, Microsoft, USA) 
and analyzed. These data included: heart rate 
during daytime (DHR) and night-time (NHR), daily 
physical activity, TI and HRV.
CRT devices calculated DHR and NHR as day-
time and night-time averages of inter-atrial interval 
lengths. Patient’s daily activity was recognized 
by the device’s sensor and was a daily average 
of minutes when the patient was active. Daily TI 
was an average of 64 impedance measurements 
taken while pacing between right ventricular coil 
and can. HRV was assessed by device using the 
median atrial HR determined every 5 min and 
variability value (SD of 5-min median atrial) was 
plotted each day.
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Analysis of device-stored temporal trends
At first, 2 reference values of every analyzed 
parameter were computed for each patient (“base-
line” levels of each variable). The first: short-term 
reference was the mean value of an appropriate 
parameter between implantation and the first 
arrhythmia. Considering the possibility, that the 
first arrhythmia (or implantable cardioverter-defi-
brillator [ICD] intervention) can change analyzed 
parameters during further observation, the second: 
long-term reference was calculated as mean within 
the whole observation period.
Subsequently, the mean values of HRVs, 
DHRs, NHRs and TIs were averaged within 4 mo - 
nitoring windows that preceded directly ICD 
intervention: within 10-day window (days –10 to 
–1), 7-day, 3-day and 1-day prior to the first ap-
propriate intervention. In patients with multiple 
adequate ICD interventions, the mean values of 
all analyzed parameters were calculated within the 
same time periods prior to all interventions and 
then averaged for every patient. If 2 arrhythmias 
were separated by less than 10 days, the second 
one was not taken into consideration.
Statistical analysis
The continuous parameters were presented 
as mean ± standard deviation or median ± range 
(depending on parameters’ distribution), categori-
cal variables as numbers and percentages. Com-
parison between the groups was performed with c2, 
T-Student or Mann-Whitney U tests, as appropriate.
To calculate arrhythmic risk 2 models were 
analyzed separately and then combined. “Stable 
risk model” included LVEF and N-terminal pro- 
B-type natriuretic peptide (NT-proBNP) values as-
sessed at baseline and after 6 months of CRT. “Dy-
namic risk model” included all device-monitored 
parameters, which changed significantly prior to 
arrhythmia. Daily risk was calculated with “stable” 
(changing one time in 6 months) and “dynamic” 
(changing daily) parameters or their combination 
included as independent variables. The predicted 
values calculated with logistic regression were 
considered indicators of daily risk. Their sum was 
a marker of cumulative risk.
Predictive power of device-based and baseline 
data was further compared using receiver-operat-
ing curves (ROC) characteristics with predicted 
risk estimates as independent variables. Predic-
tive power of combinations was compared using 
DeLong method, with pairwise comparisons of 
the areas under curve (AUC). P value < 0.05 was 
considered significant. Statistical analyses were 
performed using Statistica software package (ver-
sion 6.0 and 10.0, StatSoft Inc., Tulsa, OK, USA).
Results
Study population
During the median follow-up period of 12.03 ± 
± 6.7 months, 439 low-voltage and 68 high-volt-
age appropriate ICD therapies were launched in 
31 (32%) subjects (506 due to VT, 1 due to VF). 
Out of 507 interventions, 92 (18%) in 31 patients 
were included into further analysis. The remain-
ing 415 arrhythmias occurred nine or fewer days 
before ICD intervention in patients with multiple 
arrhythmic events, thus making it impossible to 
analyze a 10-day pre-arrhythmic period.
Patients with and without ICD appropriate 
interventions did not differ with respect to base- 
line characteristics with the exception of higher 
baseline NT-proBNP level in subjects who experien-
ced interventions (median 2251 vs. 1271 pg/mL; 
p = 0.035) (Table 1).
Outcomes and their association  
with arrhythmia
All-cause mortality was 4.5% in patients free 
of VT/VF, 6.7% in patients with one arrhythmic 
event, and 12.5% in the group with multiple ar-
rhythmias (all p = NS). Hospitalization rate due to 
exacerbated HF was higher in patients with VT/ 
/VF compared to subjects without any arrhythmia 
(35.5% vs. 13.4%, p = 0.01), being particularly high 
in patients who experienced ≥ 2 arrhythmias (43.7%, 
p = 0.005 vs. arrhythmia-free group). Similarly, 
the mean number of HF-hospitalizations/patient 
was higher in patients with than without any 
ICD intervention (0.74 vs. 0.21, p = 0.01). From 
among 92 analyzed arrhythmias in 31 patients, only 
6 (6.5%) arrhythmias in 4 (13%) patients showed 
temporal relationship to HF-exacerbation.
Changes in device-based diagnostic  
parameters prior to arrhythmia and  
their sensitivity and specificity
Considering long-term reference as a com-
parator, there was a gradual increase of DHR up 
to 103.43% of reference value within 10-day moni-
toring window before the first arrhythmia (days 
–10 to –1), reaching 103.6% within 7-day window, 
104.6% within 3-days and eventually 105.55% one 
day before intervention (all p < 0.05 vs. reference). 
Similar findings were observed in the variations of 
NHR, however a significant increase was restricted 
to 3 days before arrhythmia. On the contrary, TI 
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decreasing significantly, starting 10 days before 
arrhythmia (97.8% of reference), reaching 97.7% 
within 7-day window, 97.34% within 3 days and 
finally 96.81% of reference value 1 day before 
intervention (all p < 0.05). Daily physical activity 
and HRV did not demonstrate significant variances 
preceding ventricular arrhythmias.
In patients with multiple arrhythmias only 
increase in DHRs and NHRs heralded future ICD 
intervention, but both parameters were short-term 
forecasters (significant increase 1 and 3 days prior 
to intervention).
Taking short-term reference as baseline, DHR 
and NHR were increasing significantly 3 days be-
fore arrhythmia. TI was higher than average within 
10- and 7-day monitoring windows, to decline 
afterwards and reach reference value 3 days prior 
to arrhythmia (Fig. 1, Table 2).
Changes in device-monitored parameters 
showed only moderate sensitivity, but high speci-
ficity in predicting day-to-day probability of VT/VF 
(Table 3). The most sensitive parameter was in-
crease in DHR, the most specific parameter was 
increased HR one night prior to arrhythmia.
Combining 2 most sensitive and most specific 
parameters resulted in increasing the sensitivity 
but decreasing the specificity of such combinations. 
Combination of 3 criteria had the highest specificity 
(86.1%), without compromising sensitivity (42.3%).
After exclusion of patients with at least one 
episode of atrial fibrillation (AF) recorded by device 
(55 patients, 71% of subjects with VT/VF and 49% 
of arrhythmia-free group), the sensitivity of NHR 
in predicting VT/VF increased to 58% within 3-day 
window and to 53% one day before.
Additive role of device-based diagnostics  
in long-term and short-term arrhythmia 
prediction
Calculating the risk only on the basis of repeated 
measurements of LVEF and NT-proBNP levels 
(“stable risk model”), during 38.607 patient-days, 
median cumulative risk of experiencing arrhythmia 
was 38.9% (range 7–261%) in patients without ar-
rhythmic event and 90.4% (14–277%) in patients who 
experienced appropriate intervention (p < 0.001).
Model involving only daily-changing, device-
recorded parameters as covariates (“dynamic risk 
model” — threshold crossed for NHR 1-day before 
arrhythmia or for impedance within 7-day window 
or for DHR within 3-day window) was less efficient 
in predicting long-term risk. This model overes-
timated cumulative probability of appropriate ICD 
intervention in arrhythmia-free group (64.5%, 
range 14–197; p = 0.003 vs. stable risk model), 
whereas risk estimation in the arrhythmic group 
was similar (82.2%, 27–156, p = NS vs. stable 
risk model).
Combination of “stable risk” and “dynamic 
risk” models into one showed better long-term 
risk prediction in arrhythmia-free group (37.8%, 
range 6–256; p = 0.03 vs. baseline risk model and 
Table 1. Baseline characteristics of patients with and without appropriate implantable cardioverter-
-defibrillator (ICD)-intervention.
Patients with  
ICD-interventions (n = 31)
Patients without  
ICD-interventions (n = 65)
P
Age [years] 62 (58–70) 61 (56–70) 0.84
Female 5 (16%) 16 (25%) 0.35
NYHA IV 6 (19%) 8 (12%) 0.36
Ischemic etiology 18 (58%) 40 (61.5%) 0.74
QRS [ms] 172 (140–200) 167 (156–182) 0.59
Left ventricular ejection fraction [%] 23 (20–25) 24 (21–26) 0.17
NT-proBNP [pg/mL] 2251 (981.7–5251) 1271 (694.7–2554) 0.035
Medication at discharge [%]:
Beta-blocker 30 (97%) 65 (100%) 0.15
ACEI/ARB 30 (97%) 65 (100%) 0.15
Aldosterone antagonist 29 (94%) 63 (97%) 0.44
Loop diuretic 30 (97%) 59 (91%) 0.29
Digoxin 4 (13%) 5 (8%) 0.41
Amiodarone 2 (6.5%) 4 (6%) 0.96
Continuous variables are presented as median (range); ACEI/ARB — angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker, 
NT-proBNP — N-terminal-proB-type natriuretic peptide, NYHA — New York Heart Association functional class
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Figure 1. Heart rates (HR) (A) and thoracic impedance (B) prior to the first arrhythmia. Long-term reference — mean 
value within the whole observation period; ICD — implantable cardioverter-defibrillator.
p < 0.001 vs. dynamic risk model). Cumulative 
risk in arrhythmic patients assessed by combined 
model (83.2%, 15.4–253) was similar to the risk 
assessed separately by each of the two components 
(both p = NS).
The combined model predicted also highly ef-
fective risk of arrhythmia day-by-day, appropriately 
rating 70% of cases (AUC 0.70, 95% confidence 
interval [CI] 0.63–0.77; p < 0.05). The combination 
was moreover better that baseline risk model (AUC 
difference 0.05, 95% CI 0.0005–0.09; p = 0.04) and 
dynamic model alone (AUC difference 0.09, 95% 
CI 0.03–0.14; p = 0.003) in predicting daily risk of 
arrhythmia (Fig. 2).
Discussion
Our data indicate that some parameters moni-
tored daily by resynchronization pacemakers do 
change in specific and reproducible manner prior to 
Table 2. The variability of parameters prior to arrhythmic event.
Prior to first ICD-intervention
(31 arrhythmias/31 patients)
Prior to all ICD-intervention
(77 arrhythmias/16 patients)
Long- 
-term  
reference
Short- 
-term  
reference
Days before arrhythmia Long- 
-term  
reference
Days before arrhythmia
–10  
to –1
–7  
to –1
–3  
to –1
–1 –10  
to –1
–7  
to –1
–3  
to –1
–1
Day HR  
[bpm]
79.6 ±  
6.9
80.4 ±  
9.1
82.4 ±  
10.9*
82.5 ±  
11.2*
83.3 ±  
11.2*#
84.1 ±  
11.8*#
78.2 ±  
7.6
81.3 ±  
11.7
81.6 ±  
11.8
82.7 ±  
12.6
83.6 ±  
12.5*
Night HR  
[bpm]
69.5 ±  
7.7
70.4 ±  
9.6
71.6 ±  
10.8
71.7 ±  
10.9
72.8 ±  
11.9*#
74.8 ±  
14.7*#
70.3 ±  
7.6
73.8 ±  
11.5
73.9 ±  
11.3
75.2 ±  
12.3*
76.9 ±  
13.62*
Activity  
[min]
213.3 ±  
105
208.1 ±  
106.9
225.8 ±  
120.9
227.8 ±  
130
221.8 ±  
135.8
215.9 ±  
142.6
179.2 ±  
80.8
170.7 ±  
83.6
171.7 ±  
84.1
173.9 ±  
99.1
175.3 ±  
106.6
HRV  
[ms]
96.9 ±  
29.1
94.6 ±  
26.8
96.8 ±  
28
96.6 ±  
28.5
96.3 ±  
28.9
95.6 ±  
30.9
88.6 ±  
22.7
86.5 ±  
24.6
87.1 ±  
24.8
86.7 ±  
24.8
90.9 ±  
29.4
Impedance  
[Ohm]
65.8 ±  
7.6
63 ±  
7.5
64.3 ±  
8.3*#
64.3 ±  
8.4*#
64 ±  
8.6*
63.7 ±  
8.7*
65.8 ±  
8.5
64.9 ±  
8.6
64.9 ±  
8.8
65.1 ±  
8.8
65 ±  
9.1
*p < 0.05 vs. long-term reference (mean value within whole observation); #p < 0.05 vs. short-term reference (mean value from implant to 
first intervention); T-tests for dependent samples were used; HR — heart rate; HRV — heart rate variability; ICD — implantable cardioverter-
-defibrillator
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Table 3. Sensitivity and specificity of diagnostic parameters in predicting arrhythmias.
Parameter All patients/patients without AF
Sensitivity Specificity
DHR within 10-day monitoring window ≥ 103.4% reference 35.2%/36.8% 75.7%/76.7%
DHR within 7 days ≥ 103.6% reference 43.7%/36.8% 75.8%/76.9%
DHR within 3 days ≥ 104.6% reference 43.7%/42.1% 77.8%/79.3%
DHR 1 day before ≥ 105.5% reference 42.3%/42.1% 77.3%/78.7%
Impedance within 10 days £ 97.8% reference 35.2%/26.3% 75.5%/77.3%
Impedance within 7 days £ 97.7% reference 40.8%/36.8% 75.0%/76.8%
Impedance within 3 days £ 97.3% reference 36.6%/31.6% 74.7%/76.1%
Impedance 1 day before £ 96.8% reference 28.2%/21.1% 75.0%/76.0%
NHR within 3 days ≥ 104.7% reference 42.3%/57.9% 79.6%/80.0%
NHR 1 day before ≥ 107.6% reference 39.4%/52.6% 83.7%/83.6%
NHR 1 day or 7 days heart rate threshold crossed 54.5%/63.2% 68.6%/69.5%
DHR 7 days or 7 days impedance threshold crossed 64.8%/63.2% 56.6%/58.5%
NHR 1 day or impedance 7 days or  
DHR 3 days threshold crossed (2 of 3 criteria)
42.3%/52.6% 86.1%/86.9%
AF — atrial fibrillation; DHR — day heart rate; NHR — night heart rate
Figure 2. Receiver-operating curves comparing short-term prognostic performance of various predictive models and 
their combinations; A. Comparison of predictive model based on the left ventricular ejection fraction (LVEF) and log 
N-terminal proB-type natriuretic peptide (NT-proBNP) alone to the model with additionally included daily recorded 
device-based parameters; B. Comparison of predictive model based on device-monitored parameters alone to the 
model with  additionally included LVEF and log NT-proBNP; *Device-monitored parameters — predicted values 
calculated by logistic regression model were used for day-by-day risk assessment. The model was constructed 
with arrhythmia occurrence on the particular day as dependent binary variable and the most specific combination 
of device-monitored parameters as independent covariates. This combination included: threshold crossed for night 
heart rate (HR) 1-day before arrhythmia or for impedance within 7-day monitoring window or for day HR within 3-day 
window (1 point for each criterion: 0 to 3 points possible for a particular day); AUC — area under curve; CI — confi-
dence interval.
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ventricular arrhythmias. Variations in these parame - 
ters become significant as early as 10 days before 
arrhythmic event if long-term trends are given as 
reference. Although daily-monitored parameters 
show moderate sensitivity, they are highly specific. 
Moreover, the combination of multiple factors can 
improve their statistical performance. Our results 
suggest also an additive predictive value of device-
-monitored parameters in prognosticating both 
cumulative as well as day-by-day arrhythmic risk 
as compared to the model based only on LVEF and 
NT-proBNP.
Device-monitored parameters have been al-
ready analyzed as predictors of HF decompensation 
or death. Results of these analyses were discordant 
— non-randomized studies found device-based 
diagnostic features useful in predicting adverse 
events, but in DOT-HF randomized trial number 
of HF hospitalizations was higher in patients with 
defibrillators equipped with monitor emitting an 
alert indicating TI decrease [7, 11–19].
The evidence on the role played by device-
-tracked data in predicting ventricular arrhythmias 
is very limited. All available analyses concentrated 
on a single parameter — TI and indicated, that 
its decline heralds upcoming arrhythmic event 
[20–22]. Our observations on daily variations in 
biologic parameters preceding arrhythmia can be 
explained by several mechanisms, two of which 
seem to be the most reasonable: transiently elevat-
ed sympathetic drive and subclinical hemodynamic 
decompensation. Elevation in DHRs and NHRs 
before VT/VF may be attributed to the transient 
autonomic imbalance, with progressively more 
accented sympathetic dominance shortly before 
arrhythmia [23, 24]. Gradually faster HRs together 
with progressively declining TI prior to arrhythmia 
suggest the second mechanism involved in arrhyth-
mogenesis — hemodynamic decompensation [25]. 
Although in studied group only 6% of arrhythmias 
showed temporal relationship to HF exacerba-
tion, subclinical decompensation with volume 
overload and compensatory elevated HR is a very 
likely mechanism of arrhythmogenesis [20–22]. 
A progressively decreasing TI with initial plateau 
and subsequent fast decline prior to arrhythmia 
is difficult to explain from physiological point of 
view. This pattern of fluid overload may suggest 
excessive diuretic use by patients in initial phase of 
decompensation, leading to electrolyte imbalance 
and promoting arrhythmia.
Clinical implications
Our results suggest that during routine follow-
-up special attention should be paid to increasing 
DHR and NHR as well as decreasing TI, especially 
if multiple parameters are changing simultaneously 
in patients with no AF. These markers may be 
particularly useful in subjects without an overt HF 
decompensation. Because both HR and TI predict 
only prognosis within the next 1–7 days, their clini-
cal importance may be of limited value in conven-
tionally followed CRT patient. Nevertheless, those 
parameters may become a powerful prognostic tool, 
when combined with device remote-monitoring 
system. An automated algorithm implemented into 
devices’ software, may generate pro-arrhythmic 
alerts, warning physicians early enough to enable 
potentially protective measures. Preventive action 
would then include immediate ambulatory visit in 
order to screen for symptoms/signs of HF decom-
pensation, ongoing ischemia, electrolyte imbal-
ance, and other potentially pro-arrhythmic states.
Limitations of the study
Our study was not powered to assess the 
predictive value of device-monitored parameters. 
It was designed to compare two CRT-modes. We 
excluded the majority of arrhythmias because of 
their temporal relationship with events that were 
analyzed. However, all patients with at least one ar-
rhythmia within follow-up were analyzed. Strength 
of our study lies in its prospective, randomized de-
sign, the meticulously collected data on all adverse 
events and blind adjudication of all major adverse 
cardiac events and arrhythmias.
Conclusions
Daily device-monitored parameters show re-
producibly significant variations prior to ventricular 
arrhythmia. Combination of multiple parameters 
improves their predictive performance, whereas 
presence of AF diminishes it. Predictive value of 
these variables is additive to baseline risk factors.
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